TRACON Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 7 million compared to USD 7.71 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.4 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 USD | +2.00% | 0.00% | -56.31% |
05-14 | Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.31% | 3.41M | |
-1.62% | 89.22B | |
+1.32% | 40.49B | |
-15.76% | 32.79B | |
+64.13% | 26.23B | |
-21.32% | 14.52B | |
-8.77% | 13.09B | |
-44.07% | 11.6B | |
-13.06% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- TCON Stock
- News TRACON Pharmaceuticals, Inc.
- TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022